Stocks and Investing Stocks and Investing
Wed, February 6, 2013

Andrew Peters Maintained (BIIB) at Strong Buy with Increased Target to $170 on, Feb 6th, 2013


Published on 2024-10-25 01:51:07 -
  Print publication without navigation


Andrew Peters of Deutsche Bank, Maintained "Biogen Inc." (BIIB) at Strong Buy with Increased Target from $160 to $170 on, Feb 6th, 2013.

Andrew has made no other calls on BIIB in the last 4 months.



There are 4 other peers that have a rating on BIIB. Out of the 4 peers that are also analyzing BIIB, 3 agree with Andrew's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Christopher Raymond of "Piper Sandler" Downgraded from Buy to Hold and Decreased Target to $166 on, Thursday, January 3rd, 2013
  • Jay Olson of "Oppenheimer" Maintained at Hold with Decreased Target to $141 on, Thursday, January 3rd, 2013
  • Sumant Kulkarni of "Canaccord Genuity" Maintained at Hold with Decreased Target to $139 on, Thursday, January 3rd, 2013


This is the rating of the analyst that currently disagrees with Andrew


  • Evan Seigerman of "Credit Suisse" Maintained at Buy with Increased Target to $175 on, Monday, October 8th, 2012